Antibody Response to COVID-19 Vaccines in Liver Disease Patients

Status Completed

Clinical Trial Summary

Currently the Pfizer-Biontech (mRNA), Sinovac (inactivated virus) and Astrazeneca-Oxford (adenovirus-vector) COVID-19 vaccines are available for vaccination in HK. The American Association of Liver Disease has recently published consensus statements for COVID-19 vaccination in subjects with chronic liver disease (CLD). Patients with CLD have dysregulated innate and adaptive immune response that may be associated with vaccine hypo-responsiveness and there are no data as to whether these patients may respond differently to the various vaccines. The Humanity and Health Medical Center (HHMC) is an active participant of the HK government COVID-19 vaccination programs and patients with CLD follow-up at HHMC will have access to the three different vaccines. The aim of this prospective study is to compare the antibody response of CLD subjects to the Pfizer-Biontech (mRNA), Sinovac (inactivated virus) and Astrazeneca-Oxford (adenovirus-vector) COVID-19 vaccines.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04775069
Study type	Interventional
Source	Humanity & Health Medical Group Limited
Contact
Status	Completed
Phase	Phase 4
Start date	May 21, 2021
Completion date	September 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03704792` - Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference	N/A
Terminated	`NCT02949375` - Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease	Phase 2
Active, not recruiting	`NCT01205074` - ¹³C-Methacetin Breath Test (MBT) Methodology Study	Phase 2/Phase 3
Completed	`NCT00756171` - Colesevelam Versus Placebo in Cholestatic Pruritus	Phase 2/Phase 3
Completed	`NCT01195181` - Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.	Phase 4
Completed	`NCT05044663` - Liver and Splenic Stiffness in Predicting Esophageal Varices Needing Treatment in NASH Related Compensated Advanced Chronic Liver Disease.
Recruiting	`NCT04588077` - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis	Phase 4
Recruiting	`NCT04802954` - Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients	N/A
Recruiting	`NCT04622449` - Etiopathogenesis of Anemia in Chronic Liver Disease
Enrolling by invitation	`NCT05836246` - The Development of Quantitative Ultrasound Imaging Software Platform
Completed	`NCT03087344` - Postprandial Liver and Spleen Stiffness Measurements in the Noninvasive Diagnosis of Cirrhosis	N/A
Completed	`NCT04751045` - Comparison and Outcomes of Endoscopic Ultrasound Liver Biopsies Versus Percutaneous Liver Biopsies	N/A
Not yet recruiting	`NCT04526548` - A Diagnostic Study on Patients With Drug-induced Liver Injury
Withdrawn	`NCT02899325` - FDGal PET/CT to Detect Hepatocellular Carcinoma
Terminated	`NCT02530567` - Non-invasive Evaluation of Portal Pressure by MRI	N/A
Suspended	`NCT02650011` - Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease
Completed	`NCT01851252` - MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy	Phase 1
Terminated	`NCT01756690` - Predicting Lung Injury From Transfusion in Patients With Liver Disease	N/A
Completed	`NCT01600105` - Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)	Phase 4
Completed	`NCT01008293` - Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life	Phase 2/Phase 3